Agenus (AGEN) has risen sharply, recording gains of 25.73% in the past 4 weeks. However, the stock has corrected -3.38% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 25.25% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Agenus Inc. is up 64.66% in the last 3-month period. Year-to-Date the stock performance stands at 32.38%. The stock has recorded a 20-day Moving Average of 6.02% and the 50-Day Moving Average is 23.96%.
Agenus (NASDAQ:AGEN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.96 and $5.95 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.09. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.01, notching a gain of 0.67% for the day. The total traded volume was 652,676 . The stock had closed at $5.97 on the previous day.
Also, Equity analysts at the Brokerage firm Jefferies maintains its rating on Agenus (NASDAQ:AGEN). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Jefferies raises the price target from $6 per share to $7 per share. The rating by the firm was issued on July 29, 2016.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).